Healthcare Industry News: dilatation catheter
News Release - July 28, 2008
OrbusNeich Adds Sapphire(TM) NC Coronary Dilatation Catheter to Product Line-UpCompany Receives CE Mark Approval for Non-Compliant Balloon That Provides Controlled Strength and Superb Deliverability
HONG KONG, July 28 (HSMN NewsFeed) -- OrbusNeich today announced the addition of the Sapphire NC coronary dilatation catheter to its product line-up with the receipt of CE Mark approval. A non-compliant balloon, Sapphire NC has controlled growth of only 0.6% per atmosphere of pressure over the working pressure range for controlled dilatations. Furthermore, it has a high 22 atmospheres rated burst pressure for confident treatment of tough, calcified lesions and for post-stent dilatation.
"Sapphire NC is a reliable, easily deliverable, high performance balloon with assured results when used during percutaneous coronary intervention," said Huay-Cheem Tan, M.D., of National University Hospital in Singapore.
Sapphire NC combines advanced precision and material engineering technologies to provide optimum reliability and deliverability. The balloon catheter's HIST (HIgh Speed Tracking) tip enables flexible tracking along the guidewire, while OrbusNeich's TIFO (Tight Fold) processing results in a slender profile for enhanced crossability through tight lesions. Sapphire NC is available in a wide range of sizes for precise dilatation to match popular stent lengths.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.